Diabetes and Familial Hypercholesterolemia: Interplay between Lipid and Glucose Metabolism

被引:15
作者
Gonzalez-Lleo, Ana M. [1 ,2 ]
Maria Sanchez-Hernandez, Rosa [1 ,2 ]
Boronat, Mauro [1 ,2 ]
Wagner, Ana M. [1 ,2 ]
机构
[1] Complejo Hosp Univ Insular Materno Infantil, Endocrinol & Nutr Dept, Las Palmas Gran Canaria 35016, Spain
[2] Univ Palmas Gran Canaria, Inst Univ Invest Biomed & Sanitarias, Las Palmas Gran Canaria 35016, Spain
关键词
familial hypercholesterolemia; diabetes; LDL receptor; genetic risk; insulin resistance; review; LOW-DENSITY-LIPOPROTEIN; CORONARY-ARTERY-DISEASE; PANCREATIC BETA-CELL; CARDIOVASCULAR-DISEASE; STATIN THERAPY; RISK-FACTORS; INSULIN SENSITIVITY; RECEPTOR GENE; FOLLOW-UP; COLESEVELAM HYDROCHLORIDE;
D O I
10.3390/nu14071503
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Familial hypercholesterolemia (FH) is a genetic disease characterized by high low-density lipoprotein (LDL) cholesterol (LDL-c) concentrations that increase cardiovascular risk and cause premature death. The most frequent cause of the disease is a mutation in the LDL receptor (LDLR) gene. Diabetes is also associated with an increased risk of cardiovascular disease and mortality. People with FH seem to be protected from developing diabetes, whereas cholesterol-lowering treatments such as statins are associated with an increased risk of the disease. One of the hypotheses to explain this is based on the toxicity of LDL particles on insulin-secreting pancreatic beta-cells, and their uptake by the latter, mediated by the LDLR. A healthy lifestyle and a relatively low body mass index in people with FH have also been proposed as explanations. Its association with superimposed diabetes modifies the phenotype of FH, both regarding the lipid profile and cardiovascular risk. However, findings regarding the association and interplay between these two diseases are conflicting. The present review summarizes the existing evidence and discusses knowledge gaps on the matter.
引用
收藏
页数:23
相关论文
共 171 条
  • [1] Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
    Abifadel, M
    Varret, M
    Rabès, JP
    Allard, D
    Ouguerram, K
    Devillers, M
    Cruaud, C
    Benjannet, S
    Wickham, L
    Erlich, D
    Derré, A
    Villéger, L
    Farnier, M
    Beucler, I
    Bruckert, E
    Chambaz, J
    Chanu, B
    Lecerf, JM
    Luc, G
    Moulin, P
    Weissenbach, J
    Prat, A
    Krempf, M
    Junien, C
    Seidah, NG
    Boileau, C
    [J]. NATURE GENETICS, 2003, 34 (02) : 154 - 156
  • [2] Safety and efficacy of statin therapy
    Adhyaru, Bhavin B.
    Jacobson, Terry A.
    [J]. NATURE REVIEWS CARDIOLOGY, 2018, 15 (12) : 757 - 769
  • [3] Risk factors for cardiovascular disease in heterozygous familial hypercholesterolemia: A systematic review and meta-analysis
    Akioyamen, Leo E.
    Genest, Jacques
    Chu, Anna
    Inibhunu, Happy
    Ko, Dennis T.
    Tu, Jack V.
    [J]. JOURNAL OF CLINICAL LIPIDOLOGY, 2019, 13 (01) : 15 - 30
  • [4] Risk stratification of patients with familial hypercholesterolemia in a multi-ethnic cohort
    Allard, Matthew D.
    Saeedi, Ramesh
    Yousefi, Masoud
    Frohlich, Jiri
    [J]. LIPIDS IN HEALTH AND DISEASE, 2014, 13
  • [5] Cardiovascular disease in familial hypercholesterolaemia: Influence of low-density lipoprotein receptor mutation type and classic risk factors
    Alonso, R.
    Mata, N.
    Castillo, S.
    Fuentes, F.
    Saenz, P.
    Muniz, O.
    Galiana, J.
    Figueras, R.
    Diaz, J. L.
    Gomez-Enterria, P.
    Mauri, M.
    Piedecausa, M.
    Irigoyen, L.
    Aguado, R.
    Mata, P.
    [J]. ATHEROSCLEROSIS, 2008, 200 (02) : 315 - 321
  • [6] Lipoprotein(a) Levels in Familial Hypercholesterolemia An Important Predictor of Cardiovascular Disease Independent of the Type of LDL Receptor Mutation
    Alonso, Rodrigo
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (19) : 1983 - 1989
  • [7] Inhibition of proprotein convertase subtilisin/kexin type 9 in the treatment of hypercholesterolemia
    Ascaso, Juan F.
    [J]. ENDOCRINOLOGIA Y NUTRICION, 2016, 63 (06): : 255 - 257
  • [8] Inflammatory Biomarkers for Cardiovascular Risk Stratification in Familial Hypercholesterolemia
    Bahrami, Afsane
    Liberale, Luca
    Reiner, Zeljko
    Carbone, Federico
    Montecucco, Fabrizio
    Sahebkar, Amirhossein
    [J]. REVIEWS OF PHYSIOLOGY, BIOCHEMISTRY AND PHARMACOLOGY, VOL 177, 2020, 177 : 25 - 52
  • [9] Familial Hypercholesterolemia: The Most Frequent Cholesterol Metabolism Disorder Caused Disease
    Benito-Vicente, Asier
    Uribe, Kepa B.
    Jebari, Shifa
    Galicia-Garcia, Unai
    Ostolaza, Helena
    Martin, Cesar
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (11)
  • [10] Association Between Familial Hypercholesterolemia and Prevalence of Type 2 Diabetes Mellitus
    Besseling, Joost
    Kastelein, John J. P.
    Defesche, Joep C.
    Hutten, Barbara A.
    Hovingh, G. Kees
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 313 (10): : 1029 - 1036